Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Steroid Nasal Sprays Not Suitable For Rx-to-OTC Switch – Task Force

This article was originally published in The Tan Sheet

Executive Summary

The potential for consumers to overdose on intranasal corticosteroids without physician guidance makes the drug category inappropriate for Rx-to-OTC switch, a recent task force report finds
Advertisement

Related Content

OTC Allergy Drug Use Increases: A Symptom With Multiple Causes
OTC Allergy Drug Use Increases: A Symptom With Multiple Causes
Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review
Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review
Flonase Generic Launch Blocked; Glaxo Drops Switch Plan
Topical Corticosteroid Switches Must Overcome Side Effect Concerns – Panel
Topical Corticosteroid Switches Must Overcome Side Effect Concerns – Panel
GSK Flonase Switch Application Coming? Actual-Use Study Underway

Topics

Advertisement
UsernamePublicRestriction

Register

PS099401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel